SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. (SONN) is currently in a range/mixed trend, trading below both the 50-day and 200-day moving averages. RSI is at 28.2 (oversold), with 1/3 trend checks passing.
SONN with MA50 and MA200
Key levels & signals
Sonnet BioTherapeutics Holdings, Inc. (SONN) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $1.26, and 1 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 72.7% and below the 200-day moving average by 58.2%.
SONN currently has an RSI reading of 28.2, which suggests weaker momentum and a more oversold condition. Some traders may review this kind of setup for a rebound or buy-the-dip idea, but oversold readings by themselves do not guarantee a reversal.
Because SONN is showing a more oversold-style momentum reading inside a mixed structure, the next step is usually to watch how price behaves rather than assuming a rebound is guaranteed. Traders often want to see a stabilisation phase, a stronger reclaim, or some sign that selling pressure is starting to fade.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.
SONN shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about SONN
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.